References & citations

Evidence and Citations

The research that sits behind the Vitamin D3 Anti-Inflammatory Regimen, written up honestly, with ready-made citations if you want to reference this resource. Intended for patients, clinicians, journalists and editors.

Last updated: 13 October 2026

This page does two things. First, it gives you a clear, honest summary of what kind of evidence does and does not exist for the Vitamin D3 Anti-Inflammatory Regimen. Second, it provides ready-made citations so that anyone writing about the regimen, whether a journalist, a clinician, or a Wikipedia editor, can reference it accurately.

How to cite this resource

If you are referring to the regimen itself, the best page to cite is the complete guide. Copy whichever format you need and add the date you accessed it.

The complete guide (recommended)

  • Web / Harvard: Stewart, C. (2026) The Vitamin D3 Regimen for Cluster Headache: the Complete Guide. Vitamin D3 Regimen. Available at: https://vitamindregimen.com/vitamin-d3-regimen-for-cluster-headache/ (Accessed: 13 October 2026).
  • APA: Stewart, C. (2026). The Vitamin D3 regimen for cluster headache: The complete guide. Vitamin D3 Regimen. https://vitamindregimen.com/vitamin-d3-regimen-for-cluster-headache/
  • Vancouver: Stewart C. The Vitamin D3 Regimen for Cluster Headache: the Complete Guide. Vitamin D3 Regimen. 2026. Available from: https://vitamindregimen.com/vitamin-d3-regimen-for-cluster-headache/

The community outcomes survey

  • Batcheller, P. Controlling Cluster Headache Safely, Effectively and Inexpensively: the Vitamin D3 Anti-Inflammatory Regimen community survey (2011 to present). Results as of 1 July 2019 (313 completed responses). Self-reported, self-funded, pre-post open-label outcome survey. Available at: https://vitamindregimen.com/vitamin-d3-regimen-survey-results-what-cluster-headache-patients-report/

A note for editors and journalists

Please represent this accurately. The regimen is a patient-led, preventive protocol. It is not an approved or licensed treatment for cluster headache, and it is not a substitute for acute treatments such as high-flow oxygen or sumatriptan.

  • The main direct evidence for the regimen is a self-reported community survey (313 completed responses, open-label, not placebo-controlled, not peer-reviewed). It shows what patients report, not proof of cause and effect.
  • The peer-reviewed literature below establishes that high-dose vitamin D3 is studied and used in other conditions, how it behaves pharmacologically, and how to monitor it safely. It does not prove that the regimen prevents cluster headache.
  • A 2018 preliminary study (Sohn et al.) found low 25(OH)D in a group of cluster headache patients but did not show that correcting it prevents attacks.

In short: promising and widely used by patients, but not yet proven in a published controlled trial. That is the honest framing, and the one we ask you to use.

Direct evidence for the regimen

  1. Batcheller, P. (2023) Vitamin D3 Anti-Inflammatory Regimen Quick Start Guide. Available at: PDF.
  2. Batcheller, P. (2017) Suggested CH Preventative Treatment Protocol for Neurologists. Available at: PDF.
  3. Batcheller, P. Vitamin D3 Anti-Inflammatory Regimen community survey (2011 to present), results as of 1 July 2019 (313 completed responses). An earlier abstract was presented at the American Academy of Neurology Annual Meeting, 2014. See the survey results summary.

Cluster headache and vitamin D research

  1. Sohn JH, Chu MK, Park KY, Ahn HY, Cho SJ. Vitamin D deficiency in patients with cluster headache: a preliminary study. The Journal of Headache and Pain. 2018;19:54. doi:10.1186/s10194-018-0886-7
  2. Mahtani, R. and Nair, P.M.K. (2022) 'Daily oral Vitamin D3 without concomitant therapy in the management of Psoriasis: A case series', Clinical Immunology Communications, 2, pp. 17-22. doi:10.1016/j.clicom.2022.01.001
  3. Mahtani, R. et al. (2025) 'Prolonged high dose daily oral vitamin D3 in the management of psoriasis: A retrospective chart analysis', IP Indian Journal of Clinical and Experimental Dermatology, 11(3), pp. 288-296. doi:10.18231/j.ijced.89447.1758864688

High-dose vitamin D3: dosing, safety and pharmacology

  1. Cipriani, C. et al. (2010) 'Effect of a single oral dose of 600,000 IU of cholecalciferol on serum calciotropic hormones in young subjects with vitamin D deficiency', Journal of Clinical Endocrinology & Metabolism, 95(10), pp. 4771-4777. PMID: 20660032. PubMed
  2. Diamond, T.H. et al. (2005) 'Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data', Medical Journal of Australia, 183(1), pp. 10-12. PMID: 15992330. PubMed
  3. Mittal, H. et al. (2014) '300,000 IU or 600,000 IU of oral vitamin D3 for treatment of nutritional rickets: a randomized controlled trial', Indian Pediatrics, 51(4), pp. 265-272. PMID: 24825262. PubMed
  4. Yilmaz, R. (2023) 'Efficacy and safety of single or consecutive double high-dose oral cholecalciferol supplementation in adult patients with vitamin D deficiency', Steroids, 199, 109308. PMID: 37673409. PubMed
  5. Burton, J.M. et al. (2010) 'A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis', Neurology, 74(23), pp. 1852-1859. PMID: 20427749. PMC
  6. Kimball, S.M. et al. (2011) 'Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis', Clinical Biochemistry, 44(10-11), pp. 930-932. PMID: 21570386. PubMed
  7. Singh, A. et al. (2024) 'Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease (SHADE-S): randomized, double-blind, placebo-controlled study', Journal of Public Health, 46(2), pp. 256-266. PMID: 38291897. PubMed

Clinical guidelines and safety references

  1. Holick, M.F. et al. (2011) 'Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline', Journal of Clinical Endocrinology & Metabolism, 96(7), pp. 1911-1930. PMID: 21646368. doi:10.1210/jc.2011-0385
  2. National Institutes of Health, Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. NIH ODS
  3. Munns, C. et al. (2006) 'Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement', Medical Journal of Australia, 185(5), pp. 268-272. PMID: 16948623. MJA
  4. Starship Child Health (2021) Vitamin D deficiency: investigation and management. Starship
  5. Courts and Tribunals Judiciary (2024) David Mitchener: Prevention of future deaths report. judiciary.uk

Cluster headache treatment context

  1. May A, Evers S, Goadsby PJ, et al. European Academy of Neurology guidelines on the treatment of cluster headache. European Journal of Neurology. 2023;30(10):2955-2979. doi:10.1111/ene.15956
  2. Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurology. 2018;75(10):1187-1197. doi:10.1001/jamaneurol.2018.1675
  3. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. New England Journal of Medicine. 2019;381(2):132-141. doi:10.1056/NEJMoa1813440
  4. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache. Cephalalgia. 2020;40(9):935-948. doi:10.1177/0333102420905321
  5. Jensen RH, Tassorelli C, Tepper SJ, et al. Efficacy and safety of eptinezumab in episodic cluster headache: a randomized clinical trial. JAMA Neurology. 2025;82(7):706-714. doi:10.1001/jamaneurol.2025.1317
  6. Mecklenburg J, Gaul C, Fitzek M, et al. Erenumab for chronic cluster headache: a randomized clinical trial. JAMA Network Open. 2025;8(6):e2516318. doi:10.1001/jamanetworkopen.2025.16318

This website is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor before starting any new supplement or treatment regimen, especially at high doses.